Smith & Nephew (LSE:SN.) bucked a weak market on Thursday 22 October 2026, with the shares up about 4.2% while the wider index slipped. The FTSE 100 closed 10,725.03, down 27.85 points (−0.26%), in a risk-off session. Banks and miners dragged the index lower, a roughly 2% drop in spot gold hit precious-metals miners, and a global sell-off in technology and the AI trade weighed on growth names. Higher oil prices and lingering inflation concerns were also in focus. In that environment, a healthcare name rising by a meaningful margin was one of the more notable features of the session.

There was no company-specific announcement confirmed for the day, so there is no earnings release, deal or guidance change to point to. The gain is best understood as a reflection of defensive and healthcare demand in a risk-off market. When investors become nervous about cyclical sectors, growth stocks or commodity-linked shares, they often rotate towards areas of the market seen as steadier, and healthcare is one of the sectors commonly regarded in that way. That is the explanation consistent with the facts available, and it would be wrong to attribute the move to any specific corporate event.

Smith & Nephew is a medical-devices maker. Its products include orthopaedic implants, advanced wound care and sports-medicine products. These are used in hospitals and clinics, and demand for them is linked to healthcare activity rather than to the swings of financial markets or commodity prices. This background helps explain why the shares might attract buyers when other parts of the market are being sold, but it is general context and not news from the day.

The backdrop makes the pattern easier to follow. Banks and miners were the main drag on the index, so the FTSE 100 was being pulled down by two of its heavyweight groups. Precious-metals miners had an additional reason to fall after the roughly 2% drop in spot gold. Growth names, meanwhile, were affected by the technology and AI-trade sell-off. With those three areas under pressure, money looking for a place to sit had good reason to favour sectors that were not tied to the same drivers, and healthcare fits that description.

It is worth being cautious about over-interpreting a single session. A move of about 4.2% in a company with no announcement can reflect flows rather than a change in how the business is doing, and such flows can reverse just as quickly when sentiment shifts. If the mood improves and investors return to cyclical and growth areas, the defensive bid may fade. Equally, if risk aversion persists, defensive shares may continue to attract interest. Nothing in the information available can settle which of those is more likely.

Higher oil prices and lingering inflation concerns add another layer of uncertainty to the picture. These issues were in focus during the session and contribute to the cautious tone, though their direct effect on a medical-devices business is not something that can be established from the facts at hand. The important point is simply that the macro mood was nervous, and that Smith & Nephew was on the right side of it.

In summary, Smith & Nephew (LSE:SN.) rose on 22 October because it was viewed as a relatively defensive holding in a day when much of the market was moving the other way. No new company information was behind the move, and the shares should be understood as having traded with the sector and the market backdrop rather than on a specific announcement. In that sense the move says more about the market’s mood than about anything inside the business, and that distinction matters when judging how durable it might be.